CCIA
SRPT icon

Campbell & Co Investment Adviser’s Sarepta Therapeutics SRPT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,193
Closed -$174K – 1370
2025
Q2 		$174K Buy
10,193
+88
+0.9% +$3.75K 0.01% 1070
2025
Q1 		$645K Buy
10,105
+6,275
+164% +$661K 0.05% 581
2024
Q4 		$466K Buy
+3,830
New +$469K 0.04% 689
2024
Q3 		– Sell
-7,135
Closed -$1.13M – 1315
2024
Q2 		$1.13M Buy
+7,135
New +$917K 0.1% 317
2024
Q1 		– Sell
-4,454
Closed -$429K – 1350
2023
Q4 		$429K Buy
+4,454
New +$427K 0.04% 787
2023
Q2 		– Sell
-4,537
Closed -$625K – 1103
2023
Q1 		$625K Sell
4,537
-1,572
-26% -$204K 0.12% 327
2022
Q4 		$792K Buy
6,109
+3,977
+187% +$461K 0.19% 148
2022
Q3 		$236K Buy
+2,132
New +$215K 0.05% 561
2021
Q3 		– Sell
-2,917
Closed -$227K – 759
2021
Q2 		$227K Buy
+2,917
New +$221K 0.09% 410
2019
Q4 		– Sell
-6,703
Closed -$505K – 834
2019
Q3 		$505K Buy
+6,703
New +$792K 0.19% 170
2018
Q3 		– Sell
-2,409
Closed -$318K – 517
2018
Q2 		$318K Sell
2,409
-3,000
-55% -$283K 0.24% 174
2018
Q1 		$401K Buy
+5,409
New +$361K 0.34% 94

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Campbell & Co Investment Adviser's SRPT Position: Q3 2025 in Review

Campbell & Co Investment Adviser sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 10,193 shares — an estimated $174K sold.

Campbell & Co Investment Adviser first reported a position in SRPT in Q1 2018 and held it in 12 quarters. The position peaked at $1.13M in Q2 2024. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Campbell & Co Investment Adviser reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 10,193 Sarepta Therapeutics shares in Q3 2025, an estimated $174K.
  • Campbell & Co Investment Adviser first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 12 quarters.
  • Campbell & Co Investment Adviser's Sarepta Therapeutics position peaked at $1.13M in Q2 2024.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2025, filed 28 Oct 2025.